Transgene rights issue could fund new manufacturing plant
This article was originally published in Scrip
Transgene has launched a rights offering for a capital increase of about €152 million, after announcing its intention in March to raise around €100-150 million (scripnews.com, 24 March 2010). The French firm hopes that this will be the last fundraising it needs as it aims to become a profitable biopharmaceutical company within five years. A spokesperson told Scrip that a large part of the funds could be invested in new manufacturing facilities.